


| | | |
|---|-------------------------------------|---------------------------------|
| Form OPTO 449  US Department of Commerce Patent and Trademark Office | ATTY DOCKET NO: P-UD 3613 | SERIAL NO. 09/377,795 |
| | APPLICANT: Karin et al. | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | FILING DATE: 08/20/99 | GROUP: 1643 |

U.S. PATENT DOCUMENTS

| EXAM. INITIALS | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE |
|-------------------|--|--------------------|------|------|-------|---------------|----------------|
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| EXAM. INITIALS | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION (YES/NO) |
|-------------------|--|--------------------|------|---------|-------|---------------|-------------------------|
| | | | | | | | |


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

| | |
|--|--|
| | GenBank Accession No.: AF074382 |
| | GenBank Accession No.: R54695 |
| | GenBank Accession No.: AA133061 |
| | GenBank Accession No.: AF069542 |
| | Baeuerle and Baltimore, "NF-κB: ten years after," <u>Cell</u> 87(1):13-20 (1996) |
| | Baeuerle and Henkel, "Function and activation of NF-κB in the immune system," <u>Annu. Rev. Immunol.</u> 12:141-179 (1994) |
| | Barnes and Karin, "Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases," <u>N. Engl. J. Med.</u> 336(15):1066-1071 (1997) |
| | DiDonato et al., "A cytokine-responsive IκB kinase that activates the transcription factor NF-κB," <u>Nature</u> 388(6642):548-554 (1997) |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


COPY

| | | | |
|---|--|--|--------------------------|
| Form PTO 1449  | US Department of Commerce Patent and Trademark Office | ATTY DOCKET NO: P-UD 3613 | SERIAL NO. 09/377,795 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | APPLICANT: Karin et al. FILING DATE: 08/20/99 | GROUP: 1643 |

| | |
|--|---|
| | DiDonato et al., "Phosphorylation of I κ B α precedes but is not sufficient for its dissociation for NF- κ B," <u>Mol. Cell. Biol.</u> 15(3):1302-1311 (1995) |
| | Dumont et al., "Cross-talk between steroid and NF- κ B: what language?" <u>TIBS</u> 23:233-235 (1998) |
| | Karin, "The NF- κ B activation pathway: Its regulation and role in inflammation and cell survival," <u>The Cancer Journal from Scientific American</u> 4(1):S92-S99 (1998) |
| | Karin and Delhase, "JNK or IKK, AP-1 or NF- κ B, which are the targets for MEK kinase 1 action?" <u>Proc. Natl. Acad. Sci. USA</u> 95(16):9067-9069 (1998) |
| | Li et al., "The IKK β subunit of I κ B kinase (IKK) is essential for nuclear factor κ B activation and prevention of apoptosis," <u>J. Exp. Med.</u> 189(11):1839-1845 (1999) |
| | Ling et al., "NF- κ B-inducing kinase activates IKK- α by phosphorylation of Ser-176," <u>Proc. Natl. Acad. Sci. USA</u> 95(7):3792-3797 (1998) |
| | May and Ghosh, "Signal transduction through NF- κ B," <u>Immunology Today</u> 19(2):80-88 (1998) |
| | Mercurio et al., "IKK-1 and IKK-2: cytokine-activated I κ B kinases essential for NF- κ B activation," <u>Science</u> 278(5339):860-866 (1997) |
| | Nakano et al., "Differential regulation of I κ B kinase α and β and by two upstream kinases, NF- κ B-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1," <u>Proc. Natl. Acad. Sci. USA</u> 95(7):3537-3542 (1998) |
| | Régnier et al., "Identification and characterization of an I κ B kinase," <u>Cell</u> 90(2):373-383 (1997) |
| | Rothwarf et al., "IKK- γ is an essential regulatory subunit of the I κ B kinase complex," <u>Nature</u> 395:297-300 (1998) |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|---|--|------------------------------|--------------------------|
| Form PTO 1449  INFORMATION DISCLOSURE STATEMENT BY APPLICANT | US Department of Commerce Patent and Trademark Office | ATTY DOCKET NO: P-UD 3613 | SERIAL NO. 09/377,795 |
| | | APPLICANT: Karin et al. | |
| | | FILING DATE: 08/20/99 | GROUP: 1643 |

| | | |
|--|--|---|
| | | Sha, "Regulation of immune responses by NF- κ B/Rel transcription factors," <u>J. Exp. Med.</u> 187(2):143-146 (1998) |
| | | Verma et al., "Rel/NF- κ B/I κ B family: intimate tales of association and dissociation," <u>Genes Dev.</u> 9(22):2723-2735 (1995) |
| | | Woronicz et al., "I κ B kinase- β ; NF- κ B activation and complex formation with I κ B kinase- α and NIK," <u>Science</u> 278(5339):866-869 (1997) |
| | | Yamaoka et al., "Complementation cloning of NEMO, a component of the I κ B kinase complex essential for NF- κ B activation," <u>Cell</u> 93:1231-1240 (1998) |
| | | Zandi et al., "Direct phosphorylation of I κ B by IKK α and IKK β : discrimination between free and NF- κ B-bound substrate," <u>Science</u> 281(5381):1360-1363 (1998) |
| | | Zandi et al., "The I κ B kinase complex (IKK) contains two kinase subunits, IKK α and IKK β , necessary for I κ B phosphorylation and NF- κ B activation," <u>Cell</u> 91(2):243-252 (1997) |
| | | |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.